Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Intravenous ANX005 in Primary Cold Agglutinin Disease
2020-005854-90Phase 2Completed
- Sponsor
- Annexon Biosciences
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tanruprubart in cold agglutinin disease (CAD), sponsored by Annexon Biosciences. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Jan 2021; status: completed.
02
Drugs
tanruprubart
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on 2020-005854-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005854-90.